Skip to content

Study · Randomized controlled trial · 2024

8 results

A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer.

Niu W, Li Z, Li Z, Hu X, Wang X, Ding Y, Li C, Yu B

Biotechnology & genetic engineering reviews29 May 2023Cited by 1 (Europe PMC)

PMID37248723 (opens in a new tab)DOI10.1080/02648725.2023.2216972 (opens in a new tab)PepBankPUB-37248723
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with colorectal cancer, conventional-dose thymalfasin plus XELOX chemotherapy gave a lower incidence of perioperative infection than chemotherapy alone.

    In plain wordsIn people with colorectal cancer, thymalfasin at the conventional dose led to fewer infections around surgery than chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePerioperative infection, conventional dose
    Study

    n: not reported in source

    Comparator
    XELOX chemotherapy alone
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    1.6 mg twice a weekAs given in this study (human).

    Source sentences

    Summary
    Compared with control group, the conventional-dose group and high-dose group had notably lower incidences of perioperative infection (P < 0.05)
    2 context sentences
    Summary · context
    conventional-dose group (n = 100, 1.6 mg of thymalfasin for injection, twice a week)
    Summary · context
    In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with colorectal cancer, high-dose thymalfasin plus XELOX chemotherapy gave a lower incidence of perioperative infection than chemotherapy alone.

    In plain wordsIn people with colorectal cancer, thymalfasin at the high dose led to fewer infections around surgery than chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePerioperative infection, high dose
    Study

    n: not reported in source

    Comparator
    XELOX chemotherapy alone
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    1.6 mg thrice a weekAs given in this study (human).

    Source sentences

    Summary
    Compared with control group, the conventional-dose group and high-dose group had notably lower incidences of perioperative infection (P < 0.05)
    2 context sentences
    Summary · context
    high-dose group (n = 100, 1.6 mg of thymalfasin for injection, thrice a week)
    Summary · context
    In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with colorectal cancer, perioperative infection incidence did not differ significantly between the conventional-dose and high-dose thymalfasin groups.

    In plain wordsIn people with colorectal cancer, the two thymalfasin dose schedules did not differ significantly in infections around surgery.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changePerioperative infection, high dose versus conventional dose
    Study

    n: not reported in source

    Comparator
    Conventional-dose thymalfasin
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    1.6 mg twice or thrice a weekAs given in this study (human).

    Source sentences

    Summary
    with no significant difference in both groups (P > 0.05).
    1 context sentence
    Summary · context
    In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with colorectal cancer, the thymalfasin group had a significantly lower overall incidence of early and late postoperative complications than the control group.

    In plain wordsIn people with colorectal cancer, thymalfasin plus chemotherapy was linked to fewer early and late complications after surgery than chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePostoperative complications (early and late)
    Study

    n: not reported in source

    Comparator
    XELOX chemotherapy alone
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.6 mg twice or thrice a weekAs given in this study (human).

    Source sentences

    Summary
    The experimental group had significantly lower overall incidence of early and late postoperative complications
    1 context sentence
    Summary · context
    In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with colorectal cancer, the thymalfasin group had a significantly lower local recurrence rate than the control group.

    In plain wordsIn people with colorectal cancer, thymalfasin plus chemotherapy was linked to fewer local cancer recurrences than chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLocal recurrence rate
    Study

    n: not reported in source

    Comparator
    XELOX chemotherapy alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1.6 mg twice or thrice a weekAs given in this study (human).

    Source sentences

    Summary
    The experimental group had significantly lower overall incidence of early and late postoperative complications, local recurrence rate and the incidence of distant metastasis, and higher perioperative immune function indexes and median disease free survival (DFS) (P < 0.05).
    1 context sentence
    Summary · context
    In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with colorectal cancer, the thymalfasin group had a significantly lower incidence of distant metastasis than the control group.

    In plain wordsIn people with colorectal cancer, thymalfasin plus chemotherapy was linked to fewer distant cancer spreads than chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDistant metastasis
    Study

    n: not reported in source

    Comparator
    XELOX chemotherapy alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1.6 mg twice or thrice a weekAs given in this study (human).

    Source sentences

    Summary
    The experimental group had significantly lower overall incidence of early and late postoperative complications, local recurrence rate and the incidence of distant metastasis, and higher perioperative immune function indexes and median disease free survival (DFS) (P < 0.05).
    1 context sentence
    Summary · context
    In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with colorectal cancer, the thymalfasin group had significantly higher perioperative immune function indexes than the control group.

    In plain wordsIn people with colorectal cancer, thymalfasin plus chemotherapy was linked to higher immune function measures around surgery than chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePerioperative immune function indexes
    Study

    n: not reported in source

    Comparator
    XELOX chemotherapy alone
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg twice or thrice a weekAs given in this study (human).

    Source sentences

    Summary
    The experimental group had significantly lower overall incidence of early and late postoperative complications, local recurrence rate and the incidence of distant metastasis, and higher perioperative immune function indexes and median disease free survival (DFS) (P < 0.05).
    1 context sentence
    Summary · context
    In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with colorectal cancer, the thymalfasin group had a significantly longer median disease-free survival than the control group.

    In plain wordsIn people with colorectal cancer, thymalfasin plus chemotherapy was linked to longer median time without disease than chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMedian disease-free survival (DFS)
    Study

    n: not reported in source

    Comparator
    XELOX chemotherapy alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1.6 mg twice or thrice a weekAs given in this study (human).

    Source sentences

    Summary
    The experimental group had significantly lower overall incidence of early and late postoperative complications, local recurrence rate and the incidence of distant metastasis, and higher perioperative immune function indexes and median disease free survival (DFS) (P < 0.05).
    1 context sentence
    Summary · context
    In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.